Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early June 2021. The US patent covers the use of fimaVacc in combination with immune checkpoint inhibitors (ICIs). The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs may induce long-lasting effects in those patients responding to treatment. Unfortunately, most patients do not respond to ICI therapy and different treatment combination strategies are explored with the aim to increase the number of patients responding. Combining ICIs with therapeutic cancer vaccines that induce relevant immune responses against the tumour cells is regarded as one of the most promising strategies. The patent that soon will be granted in the US covers the use of PCI Biotech’s fimaVacc vaccination technology in combination with important classe
People are Freaking Out About Covid Infections After Vaccination yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Share
A new observational trial has started, evaluating immune responses in patients with lymphoid cancers to COVID-19 vaccines.
The Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer (PROSECO) trial aims to recruit 680 patients who will provide blood samples before and after vaccination so that clinicians can study their B and T cell responses.
Lymphoid cancers or lymphomas, originate from lymphocytes, a type of immune system cell. PROSECO is looking to recruit patient with all types of non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukaemia.
The trial will run from seven sites across the UK – the centres in Southampton, Oxford, Nottingham, Leicester, Portsmouth, Norwich are now open and another is being set up in Newcastle. Patients with lymphoid cancer are being approached by clinicians and invited to attend but patients who live in areas of participating centres are encouraged to approach their clinicians if the